《大行報告》大摩下調錦欣生殖(01951.HK)目標價至18元 評級「增持」
摩根士丹利發表研究報告,將錦欣生殖(01951.HK)的目標價由19元下調至18元,以反映疫情下國際出行限制持續,老撾項目開業時間略有延遲,抵銷試管業務的增長。
但計及10月份收購四川WCH醫院合併帶來的收益貢獻,大摩將錦欣生殖2021至2023年每股盈利預測上調至0.19、0.27及0.34元人民幣,予「增持」評級。
大摩指出,錦欣生殖目前爲中國最大的非國有生殖醫療服務供應商,在多元化服務、品牌知名度、技術能力、高成功率和市場領先地位方面具有競爭優勢,預期中國具有龐大市場潛力,同時看到併購所帶來的增長空間,以及規模效應推動的利潤率提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.